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Abstract: More efficacious and better tolerated treatments for epilepsy are clearly needed. 
Complementary and alternative medicine (CAM) has a long history of use in certain parts 
of the world and has gained increasing interest over the last decades in Western countries. 
In countries with a Western-based type of medical system, people with epilepsy (PWE) 
take natural products or engage in other forms of CAM mainly to enhance general health, 
but also to prevent seizures or to alleviate symptoms of comorbidities or side effects of 
antiepileptic medications. In other countries, well developed medical systems, such as 
traditional Chinese Medicine and Ayurveda, are often the basis for treating PWE. Based on 
anecdotal reports of efficacy in PWE, natural products from these and other traditions are 
increasingly being studied in animal models of epilepsy, and candidates for further clinical 
development have been identified. It is likely, therefore, that natural products will be 
further evaluated for safety, tolerability and efficacy in PWE with drug-resistant seizures.  
Keywords: epilepsy; natural products; complementary and alternative medicine (CAM); 
botanicals 
 
1. Introduction  
Approximately one third of people with epilepsy (PWE) have drug-resistant seizures [1,2]. Surgery 
is highly effective and safe for selected patients with treatment-resistant focal epilepsy [3,4], but is still 
underused, even in high-income countries [5]. Many PWE may not be candidates for surgery because a 
single site of origin of their seizures cannot be localized or exists within eloquent regions of the cortex. 
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Other treatment strategies are primarily palliative (vagal nerve stimulation) or still under investigation 
(closed loop cortical stimulation) [6]. Although the newer antiepileptic drugs (AEDs) may offer a 
better adverse events profile in comparison to the older generation AEDs, they may still have 
significant undesired CNS effects such as decreased cognitive abilities and psychiatric   
complications [7]. Notwithstanding these limitations, the ease of use and ready availability of 
medications, as well as the prompt reversibility of dose-related side effects, will keep AEDs as the 
mainstay of epilepsy treatment for the foreseeable future. Therefore, new drug therapies with efficacy 
against drug-resistant seizures, favorable adverse events profiles, especially in regard to neurological 
and psychiatric effects, and, if possible, low costs to patients and high worldwide availability are 
clearly needed. 
Complementary and alternative medicine (CAM) is defined by the National Center for 
Complementary and Alternative Medicine (NCCAM) as a group of diverse medical and health care 
systems, practices, and products that are not generally considered part of conventional medicine as 
practiced in the west (e.g. the United States) [8]. Four domains of practices are recognized: mind-body 
medicine (meditation, prayer, mental healing, art, music, dance), biologically-based practices (use of 
substances found in nature such as herbs, foods, vitamins, animal compounds), manipulative and body-
based practices (chiropractic or osteopathic manipulation, massage), and energy medicine (biofield and 
bioelectromagnetic therapies). Separately recognized are whole medical systems, such as homeopathy, 
naturopathy, Ayurveda and traditional Chinese medicine (TCM), each of them characterized by a 
complex and unique system of diagnostics and therapeutics. For example, the practitioners of TCM use 
herbal medicine, acupuncture and moxibustion as therapeutic methods.  
The use of different types of CAM by PWE has been comprehensively summarized [9]. Despite the 
large amount of published information on the use of different CAM interventions for epilepsy, the 
efficacy of these approaches has not been adequately proved in clinical trials. For example, three 
Cochrane reviews evaluated the published data on the use of acupuncture [10], yoga [11], and   
TCM [12] for epilepsy and none found sufficient evidence of efficacy of any of these techniques. 
Indeed, publications of CAM clinical trials for the treatment of epilepsy that have encouraging results 
generally use inadequate methodologies. Many do not adequately randomize study subjects or use 
proper controls, while others are not blinded or do not rigorously monitor the results of the 
interventions. While the requirements of evidence-based medicine have become familiar to 
conventional/western practitioners, incorporating these principles into trials of other medical systems 
is problematic because these systems may involve a holistic, personalized approach to treating patients 
rather than one that is disease focused and therefore applied in the same way to all patients 
characterized by a specific disease.  
In this article we focus on one specific CAM treatment for the treatment of epilepsy—non-vitamin, 
non-mineral natural products, and especially herbal extracts. We first review information about their 
current use by people with epilepsy around the world and then summarize available data on the 
efficacy and risks of some of these products. We conclude with possible future directions for natural 
products as epilepsy therapies. 
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2. Use of Natural Products in Countries with Western/Conventional Medical Systems 
In the 11th century, a more unified system of medicine emerged and was thereafter developed into 
what we today refer to as conventional or Western medicine, which is the principal doctrine underlying 
the diagnosis and treatment of diseases in North America, Europe, Near East, and Australia. This 
system emphasizes a disease-focused approach to diagnosis and an evidence-based approach to 
treatment. While natural products had been widely used as treatments in western medicine for 
hundreds of years, over the past century, in parallel with the development of the pharmaceutical 
industry and government regulatory agencies, single compound therapies have predominated in 
medical practice. This development reflects the evolving philosophy of Western medicine and 
requirements of regulatory agencies that treatments must have scientifically proven safety and efficacy 
in the target population. However, over the past few decades, the use of natural products by patients in 
these countries has significantly increased, driven by their search for “natural”, more effective and less 
toxic treatments and enabled by improved worldwide communication. These products are typically 
marketed as dietary supplements and often originate from established medical systems such as TCM  
or Ayurveda.  
According to the 2007 American National Health Interview Survey of 23,393 adults and 9417 
children, 38.3% of adults and 11.8% of children reported using CAM therapies [13]. These therapies 
were used more frequently by people with higher levels of education, women and the Native American 
population. The most commonly utilized form of CAM was natural products, which were used by 
17.7% of the surveyed adults. Concordantly, the annual out-of-pocket cost in the US for purchase of 
natural products for 2007 was estimated to be $14.8 billion, which is one third of the out-of-pocket 
amount spent on prescription drugs [14]. The frequency of use of specific natural products in 
developed countries appears to parallel the available evidence supporting their use. Despite an overall 
minor increase from 2002 to 2007 in the estimated frequency of CAM use by American adults (from 
36% to 38.3%), there was a marked change in the particular natural products most widely used 
between these two surveys. The survey performed in 2007 found that the most commonly used 
products were fish oil/omega-3 fatty acids (37.4%), glucosamine (19.9%), echinacea (19.8%), flaxseed 
(15.9%) and ginseng (14.1%); whereas according to the 2002 survey, echinacea was used by 40.3%, 
ginseng by 24.1%, Gingko biloba 21.1%, garlic 19.9% and glucosamine 14.9%. These trends generally 
parallel findings in the western medical literature. For example, a 2000 Cochrane review concluded 
that echinacea preparations from aerial parts of the plant were effective for the treatment of the 
common cold [15], while an update published in 2006 expressed much more equivocal   
conclusions [16]. Similarly, dietary supplementation with omega-3 fatty acids has recently become a 
mainstream recommendation for many medical conditions and especially cardiac disease [17], 
following several studies reporting decreased mortality in treated patients [18–20]. Not surprisingly, 
then, fish oil/omega-3 fatty acids was the most-often used natural product in the 2007 survey [13].  
Eleven population or hospital-based studies have investigated CAM use by adults [21–28] and 
children [29–31] with epilepsy in high-income countries (Table 1). According to these studies, 
between 24 and 56% of the adult patients and 12 to 32% of children with epilepsy have used CAM 
therapies at some time. Although only 2 to 44% of these patients reported using these products 
specifically for control of seizures, the reasons noted by many patients may be relevant to known Pharmaceuticals 2010, 3                           
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comorbidities of epilepsy such as depression or to common AED adverse events such as impaired 
memory. Some of the differences in the frequency of CAM use between studies may pertain to 
differences in the definition and types of CAM included in each study. However, another possible 
factor could be inclusion of patients with different ethnicities and cultural backgrounds, as exemplified 
by studies of patients originating from south Asia in the UK [32] and an ethnically diverse population 
in Brooklyn, New York [33]. These ethnic and cultural differences could influence the frequency of 
CAM use as well as the types of CAM used [34].  
Seven of the above mentioned studies reported the use of specific natural products in their study 
population, six of them exclusively in PWE (Table 1). We performed a Medline search on the 
characteristics of all 35 mentioned products, in regard to main uses, adverse events and potential for 
drug interactions, as well as known or presumed effects on seizures and on AEDs and report our 
findings in Table 2. Of the six reports, five included more specific numerical data on the use of natural 
products. We were therefore able to calculate percentage of overall estimates of use in PWE. Although 
integrating information from studies performed on different populations and over the course of   
10 years has clear methodological limitations, this estimate may provide helpful information for 
physicians who treat PWE.  
The three most frequently taken products were ginseng (reported by 17%), Gingko biloba (16%) 
and St. John’s wort (13%). This is interesting because these extracts are generally used for 
amelioration of symptoms of anxiety, depression and memory deficits, which are commonly 
encountered comorbidities of epilepsy [35]. While all three herbs have been reported to have beneficial 
effects on seizures, it is concerning that each has been reported to aggravate seizures as well. 
Interestingly, in the case of Gingko biloba, there is evidence to suggest that part of the plant may be 
epileptogenic (the seeds) while other parts (the leaves and the stem) may protect against seizure 
activity [36]. In contrast, the effect of St. John’s wort on seizures may depend on the extraction   
method [37]. Gingko biloba and St. John’s wort [38] may also have clinically relevant interactions 
with hepatically-metabolized AEDs. 
The next most frequently used products in this population of PWE were echinacea (11%), garlic 
(10%), cranberry (9%) and soy (8%). These are commonly used in the general population as so-called 
immune enhancers (echinacea, garlic) and for prevention and ameliorations of symptoms of urinary 
tract infections (cranberry) and menopause (soy). The higher percentages of use in PWE compared to 
the general US population [13] could potentially be explained by a lower self perceived level of 
general health among PWE, as previously suggested [39]. These products have not been reported to 
have either beneficial or detrimental effects on seizures. However, their presumed effects on the P450 
system could potentially lead to interactions with AEDs metabolized by the liver. 
Products used by 2 to 7% of PWE in the studies cited earlier include substances that may have 
specific benefits for this population. Sleep induction and anticonvulsant effects have been reported for 
melatonin [40], kava kava [41] and valerian [42], though melatonin [43] and kava kava [41] have also 
been associated with aggravation of epilepsy. Evening primrose is used for alleviation of menopausal 
symptoms, and some of its compounds have mechanisms of actions consistent with   
anticonvulsant properties [44].  
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Table 1. Publications reporting on use of CAM in countries with western style medical system. 
Publication 
Studied 
population 
% using 
CAM  
Associations 
Doctor’s 
knowledge
Most used CAM (in 
descending order, where 
known) 
Reason for use 
Outcome 
measures 
Most used non-vitamin, 
non-mineral natural 
products (in descending 
order, where known) 
Gidal et al., 
1999 [21] 
465 adults with 
epilepsy from 9 
regions in the 
US 
31%, within 
previous 
year 
Associated with 
high-school 
education or 
less. No 
influence of 
age, gender, 
seizure type. 
33%  Ginkgo biloba, vitamins 
(55%), relaxation(45%), 
ginseng, St. John’s wort 
13% epilepsy 
(relaxation, vitamins, 
herbals, homeopathy); 
28% general 
health/cold prevention; 
11% mood difficulties; 
5% cognition; 4% 
fatigue.  
NA  Gingko biloba (81% of 
users; 63% used it for 
cognition), ginseng (44% 
of users), St. John’s wort 
(used by 7% of pts.; 53% 
for mood and 24% for 
fatigue) 
Peebles et al., 
2000 [22] 
92 adults with 
epilepsy in 
Ohio (US) 
24%   No significant 
association with 
education level, 
sex, ethnicity, 
age 
31% Massage  (50%), 
herbs/supplements (41%), 
music therapy, meditation, 
art therapy, aromatherapy, 
acupuncture 
2% epilepsy (massage, 
acupuncture and 
meditation); pain; 
muscle tension; stress; 
low energy; cold; 
depression.  
NA  4 Ginseng, 3 St. John’s 
wort, 3 melatonin, 3 
Ginkgo biloba,1 garlic, 1 
black cohosh 
Waaler et al.,  
2000 [29] 
198 children 
with active 
epilepsy in 
Norway 
11.6% Additional 
neurological 
deficits 
NA Homeopathy  NA  NA  NA 
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Table 1. Cont. 
Gross-Tsur et 
al., 2003 [30] 
115 children 
with epilepsy 
in Israel 
(compared 
with children 
with ADHD 
and control) 
32% In  general  - 
higher 
education, prior 
use for current 
use; for 
epilepsy and 
ADHD - longer 
disease 
duration, less 
satisfaction 
with 
conventional 
therapy 
NA  Dietary interventions most 
and also homeopathy, 
biofeedback, acupuncture, 
Reike, reflexology, 
Shiatsu, chiropractice (in 
all groups) 
NA NA  NA 
Sirven et al., 
2003 [23] 
425 adults 
with epilepsy 
in Arizona 
(US) 
44% for 
epilepsy, 
42% for 
other 
conditions 
No association 
with education 
level 
93% 
would 
tell 
Prayer, stress 
management, botanicals, 
chiropractic (specifically 
for epilepsy) 
44% epilepsy, 42% 
other conditions 
Stress management, 
yoga and botanicals 
subjectively most 
beneficial. 43% 
using botanicals for 
epilepsy had 
increased seizure 
frequency; 3 had 
major side effects 
(intracranial 
hemorrhage with 
ephedra).  
General/epilepsy use: 
76/13 Garlic, 157/12 
gingko, 64/10 soy, 40/11 
melatonin, 22/10 kava, 
159/8 ginseng, 147/9 St. 
John’s wort, 89/9 
Echinacea, 68/3 cranberry, 
40/5 goldenseal, 24/7 
grapeseed, 21/4 black 
cohosh, 33/4 valerian, 14/3 
saw palmetto, 7/7 evening 
primrose, 12/2 licorice, 7/4 
hops,3/2 black haw 
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Plunkett et 
al., 2004 [24] 
187 adults 
with epilepsy  
in San 
Francisco area 
(US) 
56% No  association 
with seizure 
frequency or 
with having 
adverse events 
from AED. 
68%  Vitamins or minerals 
supplements 
3% epilepsy or AED 
adverse events; general 
health; supplementing 
diet; physician’s 
recommendation. 
NA 
(19% used products 
wit cyp450 activity 
and 14% - 
potentially 
epileptogenic 
agents.) 
Garlic, echinacea, St. 
John’s wort, ephedra, 
ginseng, gingko, evening 
primrose 
Yuncker et 
al., 2004 [31] 
350 children 
with 
neurological 
conditions 
(60% had 
epilepsy) in 
Pennsylvania 
(US) 
28% of 
children 
with 
epilepsy 
(37% of all 
conditions) 
Diagnosed for 
less than one 
year 
69% NA  NA  87%  overall  felt 
CAM was 
effective and 
similar to 
conventional 
therapy. 40% 
knew possible 
side effects. 
NA 
Easterford et 
al., 2005 [25] 
377 adults 
with epilepsy 
in Manchester, 
UK 
34.6% Higher 
education 
37%  NA  11.1% epilepsy  No significant 
effect on seizure 
frequency. CAM 
was cheap. 
NA 
Liow et al.,  
2007 [26] 
228 adults 
with epilepsy 
in mid west 
US 
39%   No association 
with education 
level 
49% Prayer/spirituality, 
megavitamins, 
chiropractic, stress 
management 
57 (25%) epilepsy: 33 
prayer/spirituality; 14 
megavitamins; 11 
chiropractic; 11 stress 
management 
Subjective benefit 
of 74% of 57. 
Only few side 
effects. Increased 
szs in diet pills, 
chiropractic, 
ketogenic diet, 
atkin’s 
megavitamins. 
10 Cranberry, 8 black 
cohosh, 7 Echinacea, 6 
melatonin, 4 garlic, 4 grape 
seeds, 4 soy, 4 St. John’s 
wort, 4 valerian, 3 evening 
primrose, 2 Ginkgo biloba, 
2 ginseng, 1 black haw  
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Murphy et 
al., 2008 [27] 
671 adults 
with 
neurological 
conditions in 
Ireland (189 
with epilepsy) 
47.6% of 
patients with 
epilepsy 
(63.3% of all 
conditions) 
NA 25%  for 
all 
conditions
massage, acupuncture, 
vitamins, reflexology, 
yoga, evening 
primrose/starflower oil, 
chiropractic, homeopathy 
(for all conditions) 
NA Most  had 
subjective benefit. 
Annual cost was 
1170.32 euro.  
97 evening 
primrose/starflower oil, 24 
marijuana, 16 St. John’s 
wort, 16 Gingko biloba, 
Udo’s oil, fish oil, black 
cohosh, echinacea, 
bonemeal, coenzyme Q-10 
Kaiboriboon 
et al., 2009 
(only use of 
herbs and 
dietary 
supplements 
was studied) 
[28] 
187 adults 
with epilepsy 
at UCSF 
medical center 
(US) 
56% 
(current 
use) 
Partial epilepsy 
and Caucasian 
race. No 
association with 
gender, age, 
level of 
education, 
income, 
duration of 
epilepsy or 
seizure 
frequency. 
71%  Multivitamins and minerals, 
folic acid, ginseng, Ginkgo 
biloba, glucosamine and 
chondroitin, St. John’s wort, 
black cohosh, Echinacea, 
evening primrose, ephedra, 
caffeine, melatonin, milk 
thistle, omega 3, kava, 
skullcap, valerian, 
grapefruit juice, glutamine, 
clover/nettles, parsley leaf, 
DHEA, Coenzyme Q10, 
ginger, fish oil, garlic, grape 
seed, L-lysine 
6 epilepsy (kava, 
skullcap, valerian, 
folic acid, vit. B6, vit. 
E, multivitamins, 
minerals); 35 general 
health; 13 physician’s 
recommendation; 13 
improve bone density; 
10 increase energy; 10 
boost immune system; 
7 improve memory. 
9 patients reported 
adverse events 
that they 
attributed to these 
products. None 
reported 
aggravation of 
seizures. 88% of 
patients spent less 
than $50 a month 
and only 5% spent 
more than $100. 
4 Ginseng, 4 Ginkgo 
biloba, 4 glucosamine and 
chondroitin, 3 St. John’s 
wort, 2 black cohosh, 2 
Echinacea, 2 evening 
primrose, 2 ephedra, 2 
caffeine, 2 melatonin, 2 
milk thistle, 2 omega 3, 1 
kava, 1 skullcap, 1 
valerian, 1 grapefruit juice, 
1 glutamine, 1 
clover/nettles, 1 parsley 
leaf, 1 DHEA, 1 
Coenzyme Q10, 1 ginger, 
1 fish oil, 1 garlic, 1 grape 
seed, 1 L-lysine  
CAM—complementary and alternative medicine; NA—not available; AED—anti-epileptic drug. 
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Table 2. Characteristics of natural products used by patients with epilepsy in countries with western based type of medical system. 
Product Main  current  medical  uses  Main adverse events & interactions  Overall 
estimated 
extent of use 
in PWE*  
Possible effects in 
epilepsy 
Potential risks for PWE 
Black cohosh 
(Cimicifuga 
racemosa) 
[22,23,26-28
$] 
Ameliorates menopausal symptoms  Possible hepato-toxicity  4%  NR  NR 
Black haw 
(Viburnum 
prunifolium) [23,26] 
Spasmolytic, sedative, anti 
asthmatic 
NR <1%  NR  NR 
Bonemeal [27]  Calcium supplementation (not used 
recently) 
Possible prion infection    NR  NR 
Seizures secondary to 
lead poisoning 
Caffeine [28
$]  Stimulant, antinociceptive  Sympathomimetic and GI symptoms   <1%  NR  Associated with seizures. 
May interact with CBZ. 
Chondroitin [28
$]  Anti arthritis & arthralgia  GI symptoms, hypersensitivity, possible 
anticoagulation (increased INR with Warfarin) 
<1% NR  NR 
(Red) clover 
(Trifolium pretense) 
[28
$] 
Ameliorates menopausal symptoms  Possibly inhibits aromatase and extrahepatic 
CYP1A1, 1B1. May increase INR when taken with 
Warfarin 
<1% NR  NR 
Coenzyme Q10 
[27,28
$] 
Antioxidant, ameliorates CHF and 
neurodegenerative disorders 
May increase risk of bleeding in Warfarin users  <1%  May improve 
seizures in 
neurological 
mitochondrial 
diseases 
NR 
Cranberry [23,26]  Prevents UTI, cardioprotector, anti-
cancer, antioxidant 
GI intolerance, weight gain, possibly 
thrombocytopenia and increase in INR in 
combination with Warfarin 
9% NR  NR 
Inhibited P450 system in 
vitro, but not in vivo. 
DHEA [28
$]  Hormonal replacement therapy in 
elderly women and men 
No adverse events. Induces CYP2B6  <1%  NR 
No effect in animals 
Possibly associated with 
seizures Pharmaceuticals 2010, 3                                       
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Table 2. Cont. 
Echinacea 
[23,24,26-28
$] 
Enhances immune system functions  Hypersensitivity, GI disturbance, hepatotoxicity 
with prolonged use; mild effect on CYP3A4 and 
CYP1A2 
11% NR  NR 
Ephedra [24,28
$]  Induces weight loss, stimulant  HTN, tachycardia, stroke  <1%  NR  Associated with seizures 
Evening primrose 
(Oenothera biennis) 
[23,24,26-28
$] 
Ameliorates menopausal symptoms  NR  2%  Anti-seizure effects 
(animals) 
Possibly associated with 
seizures 
Garlic [22-
24,26,28
$] 
Antioxidant, cardiovascular, cancer 
prevention, immune stimulant 
GI disturbance, dizziness. Possible increase in INR, 
HTN, arrhythmia. Possible influence on CYP3A4 
and inhibitor of CYP2C9/19 
10% NR  NR 
Ginger [28
$]  Prevents cardiovascular disease and 
cancer, ameliorates GI symptoms, 
antioxidant, anti-inflammatory 
May increase risk of bleeding in warfarin users. 
Possible inductor of CYP1A2 and 3A4 
<1% May  have 
antiepileptic effects  
NR 
Ginseng [21-
24,26,28
$] 
Anxiety, depression, concentration 
problems, DM, stimulant, 
menopausal symptoms, sexual 
dysfunction in men 
Possible hepatotoxicity & increased INR, lethargy  17%  May have 
anticonvulsive 
properties 
May exacerbate seizures 
Ginkgo biloba [21-
24,26-28
$] 
Cognitive enhancer, prevents 
cardiovascular disease, antioxidant 
GI discomfort, anti-coagulant. May inhibit CYP2B6 
and induce CYP3A & 1A2, 2C19. 
16%  Leaves and stems 
may be 
anticonvulsive 
Seeds may be toxic and 
pro-convulsive. May 
increase metabolism of 
AED (PHT, VPA, PB) 
Glucosamine [28
$]  Anti-arthritis & arthralgia  May increase INR in warfarin users.  <1%  NR  NR 
Glutamine [28
$]  Enhances healing after injury, 
especially GI, promotes muscle 
building 
NR <1%  NR  NR 
Goldenseal 
(Hydrastis 
Canadensis) [23] 
Anti-inflammatory, anti-microbial  Possible hypernatremia, HTN, edema. Strong 
inhibitor of CYP2D6 & CYP3A4/5, CYP2E1 
5% NR  NR 
Grapefruit juice 
[28
$] 
Prevents cardiovascular disease and 
cancer, antioxidant 
Inhibits enteric CYP3A4, possibly increases risk of 
breast cancer 
<1% NR  Increases  bioavailability 
of CBZ, BDZ 
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Grape seeds 
[23,26,28
$] 
Prevents cardiovascular disease and 
cancer, antioxidant 
Hypersensitivity, HA, dizziness, nausea. May 
inhibit CYP2E1 
4% NR  NR 
Hops (Humulus 
lupulus) [23] 
Ameliorates anxiety, insomnia and 
menopausal symptoms, anti-
inflammatory, antioxidant  
Sedation. Possibly inhibits CYP2C9, 1A1/2, 1B1  <1%  NR  Possibly exacerbates 
seizure 
Kava kava (Piper 
methysticum) 
[23,28
$] 
Ameliorates depression, anxiety 
and insomnia, induces local 
anesthesia 
Possibly psychosis, choreoathetosis, hepatotoxicity, 
dermopathy, lymphopenia, GI disturbances, 
potential for addiction. Inhibitor of CYP2E1, 1A2, 
induction of 1A1. 
4%  May benefit  Possibly exacerbate 
seizures 
L-lysine [28
$]  Precursor of carnitine, promotes 
protein building, anti-cancer, anti-
viral 
NR <1%  NR  NR 
Licorice (liquorice 
or Glycyrrhiza 
glabra) [23] 
Expectorant, anti-viral, anti-
spasmodic, ameliorates gastric & 
duodenal ulcers, and menopausal 
symptoms 
In overdose - hypokalemia and increase in BP, 
decrease testosterone in men. May increase INR 
when taken with warfarin. Possibly inhibits 
CYP3A4, 2B6, 2C9. 
2% NR  NR 
Marijuana 
(Cannabis sativa) 
[27] 
Antinociceptive, ameliorates 
glaucoma, anti-nausea, muscle 
relaxant, promotes bone health 
Tachycardia, dry mouth, red eyes, euphoria, 
anxiety, psychosis, memory deficit. Possibly 
induces CYP2E1 
  May benefit   May exacerbate seizures 
Melatonin 
[22,23,26,28
$] 
Ameliorates insomnia, circadian 
rhythm abnormalities, depression, 
and anxiety 
HA, nausea, somnolence  7%  May benefit  Associated with increased 
seizure frequency 
Milk thistle [28
$] Ameliorates  hepatotoxicity  and 
DM, anticancer 
Possible downregulation of CYP3A4, 2C9  <1%  NR  NR 
Nettles (Urtica 
dioica) [28
$] 
Antinociceptive, anti-arthritis, 
antioxidant, diuretic, ameliorates 
BPH 
Uterine stimulant  <1%  NR  NR 
Omega 3/fish oil 
[27,28
$] 
Cardioprotective, ameliorates 
depression, dementia, ADHD 
Anti-coagulant <1%  May  be  beneficial 
(SUDEP) 
NR 
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Table 2. Cont. 
Parsley leaf [28
$] Diuretic,ameliorates  constipation, 
promotes bone health 
May increase INR when taken with warfarin. 
Possibly downregulates p450. Possibly stimulates 
uterine contractions. 
<1% NR  NR 
Saw palmetto 
(Serenoa repens) 
[23] 
Ameliorates UTI and BPH  GI disturbance, HA, decreased libido. Inhibition of 
CYP3A4, 2D6, 2C9.  
2% NR  NR 
Skullcap 
(Scutellaria) [28
$] 
Sedative, anti-epileptic, hypnotic, 
anxyolytic, anti-cancer 
NR <1%  May  benefit 
 
NR 
Soy [23,26]  Source of Omega 3 & 6 fatty acids. 
Ameliorates menopausal 
symptoms, prevents prostate 
cancer, and promotes bone health 
May increase risk of developing breast cancer. 
Possibly inhibit CYP2A6, 1A1, 1B1, 3A4. 
8% NR  NR 
St. John’s wort 
(Hypericum 
perforatum) [21-
24,26-28
$] 
Ameliorates depression, pain, 
ADHD 
Possibly hepatotoxicity, visual disturbances, 
paresthesia, myalgia, GI disturbances, sedation, 
photosensitivity. Inducer of CYP3A4, 2E1, 2C19, 
P-glycoprotein. Possible inhibition of CYP2C9/19, 
2D6, 3A4, 1A2. Avoid MAO inhibitors and SSRIs. 
13%  Possible benefit  Possibly associated with 
seizures 
Valerian [23,26,28
$]  Ameliorates anxiety, insomnia, and 
epilepsy, nociceptive 
GI disturbance, drowsiness, HA. Avoid barbiturates. 
Possibly inhibits CYP2D6, 3A4 
5% May  benefit  NR 
* The overall extent of use was calculated by combining data from the publications that provided numerical data for the use of specific products. For 
Ginseng, Gingko biloba and St. John’s wort, the information was taken from the publications by Gidal, Peebles, Sirven, Liow, and Kaiboriboon (on a total 
of 1407 PWE) and for all other products from the publications by Peebles, Sirven, Liow, and Kaiboriboon (on a total of 942 PWE) (see last column of 
Table 1 for enumeration of use of natural products). 
$This reference reports on neurological conditions in general, including epilepsy. PWE—people with 
epilepsy; NR—not reported; GI—gastro-intestinal; CHF—congestive heart failure; UTI—urinary tract infection; HTN—hypertension; BHP—benign 
hypertrophy of prostate; SUDEP—sudden unexplained death in epilepsy patients; HA—headache; AED—anti-epileptic drugs; PHT—phenytoin; VPA—
valproic acid; PB—phenobarbital; CBZ—carbamazepine; BDZ—benzodiazepines. Pharmaceuticals 2010, 3                           
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Other infrequently used products mentioned in the studies that have anecdotally been reported to 
have beneficial effects on seizures, epilepsy comorbidities or complications of epilepsy are skullcap 
(anticonvulsant, sedative [45]), grapefruit juice (sedative [46]), hops (sedative [47]), and omega-3 fatty 
acids (treatment of epilepsy and prevention of SUDEP [48]). However, others have been linked to pro-
convulsive effects, such as ephedra and caffeine [49]. In addition, grapefruit juice is a potent inhibitor 
of the enteric P450 system, therefore increasing the bioavailability of many drugs, including   
certain AEDs [46].  
The efficacy of natural products for control of seizures cannot be accurately assessed from the 
available studies because of their significant methodological shortcomings. For example, only one 
study assessed efficacy using a generally accepted method, i.e. the medical notes of treating   
physicians [25]. However, patients typically report overall subjective benefit in these studies; whether 
this is consistent with the general population’s view of CAM as “natural” and therefore beneficial 
requires further study.  
Because of the risk of pharmacokinetic interactions with AEDs, it is concerning that many patients 
do not inform their physicians about their use of natural products [21,22,25–27]. Two publications 
noted that treatment with natural products was generally widely affordable [25,28], whereas a third one 
reported on a relatively high annual cost of 1170 euro [27]. 
3. Use of Natural Products in Countries Where Traditional Medicine Is Widely Practiced 
The CAM therapies found in regions with widely practiced forms of traditional medicine are 
generally much more diverse than in countries with a strong western-based type of medical system. 
This diversity may arise from the relatively lower financial resources of patients in addition to the 
availability of and access to traditional medicine systems. For example, in sub Saharan Africa, limited 
financial resources restrict access to western-style medicine, and most persons live very traditionally, 
with mystical beliefs influencing their day-to-day lives and affinity for traditional healers. There are 
notable exceptions, such as high-income countries like South Korea and Japan with well-developed 
systems of traditional medicine practiced alongside western-style medicine.  
Ayurveda and TCM are among the best known systems of traditional medicine. Ayurveda 
originated thousands of years ago and continues to be widely practiced in South Asia, especially in 
India. TCM is widely practiced and carefully regulated by the Chinese government. The Kampo 
system in Japan, as well as Korean Oriental Medicine (KOM), are derived from TCM and remain 
broadly similar.  
Ayurveda—This is the oldest known system of medicine, developed by the ancient Hindus, and 
based on balancing the three elements (vata, pitta, kapha) in the human body. Epilepsy (Apasmara) is 
considered a mental disease and classified into four types, three with predominant involvement of each 
of the three elements and a fourth characterized by combined involvement of all three. Although some 
characteristics of seizures as defined in western medicine also appear in Ayurvedic writings, there are 
differences in how seizures are recognized between these two systems. Treatment usually starts with 
drastic cleansing of the body through emesis, enemas and purgatives, followed by different Ayurvedic 
drug formulations. Additional Ayurvedic drugs are then recommended for use and are administered by 
various ways: orally, by nasal or ocular application, anointing the body or by fumigation [50]. Pharmaceuticals 2010, 3                           
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Ayurvedic practitioners prescribe PWE mixtures of natural products, containing herbal extracts, as 
well as animal ghee, honey and milk. The most widely used herbal extracts are prepared from Acacia 
arabica, Acorus calamus, Bacoppa monnieri, Clitorea turuatea, Celastrus panniculata, Convulvulus 
pluricaulis, Emblica officinalis, Mukta pishti, Whithania somnifera, and Vaca brahmi yoga [51]. 
TCM—This medical system concerns the study of human physiology and pathology, and the 
prevention, diagnosis and treatment of human diseases, and dates back more than 2500 years [52]. The 
theory of TCM for PWE is difficult to understand from a western perspective because of the TCM 
approach to diagnosis and treatment, and the related principles of holism and differentiation. Four 
subtypes of epilepsy are recognized, but, as is the case with the classification of seizures in Ayurveda, 
they do not match directly to the ILAE classification of seizures and epilepsies. Treatments typically 
involve mixtures of different herbal extracts (each containing many active compounds), some to 
directly treat the seizure disorder and others to maintain the general wellbeing of the host. The 
treatment may be applied in three phases. First, seizures are treated by herbs and acupuncture; then, 
herbs, acupuncture and moxibustion are used for tonic strengthening of organs; and finally, daily life 
guidelines are recommended to prevent relapse [52].  
The most frequently used herbal medicines in the published clinical epilepsy literature from the Far 
East are Pinella ternate, Arisaemi japonicum, Acorus calamus, Gastrodia elata, Buthus martensii, 
Poria cocos, Bombyx bartryticatus, Citrus reticulate, Uncaria rhynchophylla, Glycyrrhiza glaba, 
Salivae miltiorrhizae, Scolopendra subspinipes, Bupleurum falcatum, Succinum, Paeonia albiflora, 
Panax ginseng, Perichaeta communissma and Curcuma longa [51]. However, as mentioned earlier, 
there is insufficient evidence at the present time to recommend the use of TCM for treatment of 
epilepsy [12]. Nevertheless, extracts used for seizure control in TCM, as well as single compounds 
derived from these extracts, are being tested alone and in combinations for anticonvulsant effects in 
animal models of epilepsy.  
Sub-Saharan African practices—In this region of the world, there is no widely practiced 
traditional medical system, such as TCM. Individual local healers acquire their skills from their 
teachers of the previous generation and different healers may have different approaches to the 
diagnosis and healing processes as well as a different array of therapeutic products. Although heredity 
is acknowledged as an etiologic factor, epilepsy is frequent thought to be contagious or provoked by 
witchcraft, and burns are considered a sign of intractable disease [53,54]. Some healers only recognize 
epileptic seizures as those that would be classified in the west as generalized tonic-clonic seizures [53], 
whereas others may use broader definitions [54]. Treatments are based on spiritual measures and 
natural products derived from herbs and animals that naturally exhibit behavior resembling 
convulsions or loss of consciousness. 
Tens of botanicals have been reported to be used in the treatment of epilepsy in different parts of 
sub Saharan Africa [55–57], by oral delivery, inhalation and topical application. However, there is 
inadequate study of these treatments to understand their relative frequency of use, efficacy and   
adverse events. 
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4. Perspectives for the Future 
Western-style clinicians should educate their patients about the potential problems associated with 
natural products and should encourage their patients to inform them when using these products, so that 
potential adverse effects on seizures and plasma concentrations of AEDs can be monitored. In 
addition, symptoms of comorbid conditions may come to light and perhaps be more effectively treated. 
Counseling patients requires that clinicians become familiar with the natural products commonly used 
by their patients. Patients should understand the current differences in manufacturing of dietary 
supplements and pharmaceuticals. In the US, herbal medicines have been regulated by the 1994 
Dietary Supplement and Health Education Act, which did not require manufacturers to use good 
manufacturing practice (GMP) standards, which is the case for pharmaceuticals. However, in 2007 the 
FDA issued “current good manufacturing practice in manufacturing, packaging, labeling, or holding 
operations for dietary supplements” [58]. This new regulation will prevent significant variation from 
lot to lot, bottle to bottle, or pill to pill for any dietary supplement [59].  
In developing countries, natural products may be more accessible, culturally acceptable and 
affordable then “western” medicines. Therefore, there is a need to scientifically study the safety and 
efficacy of natural products that are available and recommended by local healers in these regions. The 
principles of evidence-based medicine apply to these products just as much as they do for   
single compounds.   
Indeed, the publication of FDA guidelines for the approval of herbal products for specific 
indications [60] has sparked an interest in developing strategies for systematically evaluating the 
efficacy and safety of these products, and increases the potential for industry to invest in their clinical 
development. In the case of epilepsy therapies, evaluation of candidate products in animal models of 
epilepsy should precede clinical studies, as is done with pharmaceuticals. Notably, there was a more 
than 4-fold increase in the number of papers found on PubMed reporting pre-clinical studies of herbal 
products or their derivatives from 9 in 1998–1999 to 37 in 2008–2009. Some studies report in vivo 
effects and others on mechanisms of action.  
A recent article grouped the new investigational drugs for epilepsy into several categories [61]:  
i. modifications of existing AEDs to enhance their efficacy and safety; ii. New molecular targets and 
classes of drugs; derived from knowledge of the mechanisms underlying epilepsy and epileptogenesis; 
iii. Miscellaneous substances first found to have antiepileptic activity and subsequently being 
evaluated for their mechanisms of action. The investigation of natural products for use in epilepsy has 
proceeded using the second and third strategies. One such approach is to test natural products for 
actions relevant to known mechanisms of actions of AEDs. This approach has the advantage of being 
able to screen a large number of products at once. At the request of healers, Awad et al. tested   
34 plants used by the Q’eqchi’ Maya to treat epilepsy and anxiety for their ability to inhibit gamma 
aminobutyric acid transaminase (GABA-T) and to bind to the benzodiazepine (BDZ) site of the GABA 
A receptor [62]. At the highest tested concentrations, they found greater than 50% inhibition of 
GABA-T by 10 plants and greater than 50% binding to the GABA A receptor by 23 plants. 
Interestingly, a positive correlation was found between the degree of GABA-T inhibition and 
frequency of use for epilepsy and between the degree of affinity to the receptor and frequency of use 
for anxiety, suggesting a plausible scientific basis to their use. However, the correlation coefficients Pharmaceuticals 2010, 3                           
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were low, implying that other mechanisms may also be important. The limitation of the approach used 
in this study is that by design it focuses on a known mechanism of action and therefore is not likely to 
identify natural products with unique mechanisms of action.  
Another interesting approach is to screen plants for potential activity in models of   
epileptogenesis [63]. Sucher screened natural products traditionally used in TCM for stroke, and 
assessed activity at multiple molecular targets in the glutamate-receptor triggered signaling pathway 
leading to neuronal injury and death. He found that many of the herbal drugs contained different 
compounds that act with low affinity at multiple molecular targets in the pathway. Since these 
processes occur in parallel and may be hypothesized to predispose to the development of chronic 
epilepsy after different types of brain injury, he proposed that their combined synergistic activity may 
give rise to neuroprotective and, possibly, antiepileptogenic effects, with a good safety profile.  
A third approach, used by the authors of this article, is to: (1) identify herbal therapies and 
compounds isolated from them that have promising activity in animal epilepsy models and/or relevant 
in vitro assays; (2) conduct the pre-clinical studies necessary to proceed with early stage clinical 
studies; and (3) plan and initiate these clinical studies. Extracts and mixtures of extracts of herbal 
therapies, as well as pure compounds isolated from them, are first identified based on clinical 
recommendations of herbal experts around the world, review of original text references, and published 
results of laboratory or clinical studies. To date, 30 products have been studied in animal models of 
epilepsy, pain and neuroprotection through the NINDS Anticonvulsant Screening Project (ASP) and in 
in vitro assays of neuronal receptor or ion channel function. Twenty one of these products (70%) have 
proven to be active. One compound, huperzine A, has shown potent anticonvulsant and antinociceptive 
activity in rodent models [64,65] and is the subject of the first clinical trial from   
our program.  
5. Summary 
Natural products are widely used by PWE all over the world, but there is currently little evidence of 
safety and efficacy to scientifically justify their use. Nonetheless, natural products with a long history 
of medicinal use in epilepsy or relevant mechanisms of action should be further tested using systematic 
pre-clinical methods and rigorously studied in PWE where appropriate as potential new treatments  
for epilepsy. 
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